Plasma urocortin 1 in human heart failure

Circulation: Heart Failure

Volumn 2, Issue 5, 2009, Pages 465-471

  Wright, Sue P ^a   Doughty, Robert N ^a   Frampton, Chris M ^b   Gamble, Greg D ^a   Yandle, Tim G ^b   Richards, A Mark ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adrenomedullin; Cardiac natriuretic peptides; Endothelin; Heart failure; Urocortin

Indexed keywords

ADRENOMEDULLIN; CREATININE; ENDOTHELIN 1; NATRIURETIC FACTOR; NEUROHORMONE; UROCORTIN I; BIOLOGICAL MARKER; UROCORTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ECHOGRAPHY; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ROC CURVE; STATISTICAL MODEL; UPREGULATION;

ADRENOMEDULLIN; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CREATININE; ENDOTHELIN-1; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; UP-REGULATION; UROCORTINS; VENTRICULAR FUNCTION, LEFT;

EID: 70350448974     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.840207     Document Type: Article

References (38)

1. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CMJ, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol. 2002;40:1495-1505.
2. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation. 2005;112:3624-3632.
3. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Endogenous urocortins reduce vascular tone and renin-aldosterone/ endothelin activity in experimental heart failure. Eur Heart J. 2005;26:2046-2054.
4. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J. 2005;26:2055-2062.
5. Rademaker MT, Charles CJ, Richards AM. Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H1536-H1544.
6. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, Frampton CM, Richards AM. Effect of urocortin-1 infusion in humans with stable congestive cardiac failure. Clin Sci. 2005;109:381-388.
7. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards M. Urocortin 2 infusion in human heart failure. Eur Heart J. 2007;28:2589-2597.
8. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjos OD, Latchman DS, Lee K-F, Vale W. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004;145:24-35.
9. Chang CL, Hsu SYT. Ancient evolution of stress-regulating peptides in vertebrates. Peptides. 2004;25:1681-1688.
10. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, Rivier J, Sawchenko PE, Vale W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378:287-292.
11. Hsu SY, Hsueh AJW. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001;7:605-611.
12. Imaki T, Katsumata H, Miyata M, Naruse M, Imaki J, Minami S. Expression of corticotropin releasing factor (CRF), urocortin and CRF type 1 receptors in hypothalamic-hypophyseal systems under osmotic stimulation. J Neuroendocrinol. 2001;13:328-338.
13. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 2001;98:7570-7575.
14. Scarabelli T, Knight R. Urocortins: take them to heart. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:335-342.
15. Eckart K, Radulovic J, Radulovic M, Jahn O, Blank T, Stiedl O, Spiess J. Actions of CRF and its analogs. Curr Med Chem. 1999;6:1035-1053.
16. Iino K, Sasano H, Oki Y, Andoh N, Shin R-W, Kitamoto T, Takahashi K, Suzuki H, Tezuka F, Yoshimi T, Nagura H. Urocortin expression in the human central nervous system. Clin Endocrinol. 1999;50:107-114.
17. Muramatsu Y, Fukushima K, Iino K, Totsune K, Takahashi K, Suzuki T, Hirasawa G, Takeyama J, Ito M, Nose M, Tashiro A, Hongo M, Oki Y, Nagura H, Sasano H. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides. 2000;21:1799-1809.
18. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol. 2000;279:H3031-H3039.
19. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol. 2004;143:508-514.
20. Brar BK, Stephanou A, Okosi A, Lawrence KM, Knight RA, Marber MS, Latchman DS. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol. 1999;158:55-63.
21. Ikeda K, Tojo K, Tokudome G, Hosoya T, Tajima N, Oki Y, Asaba K, Hashimoto K, Harade M, Nakao K. Urocortin is an endogenous cardioprotective factor against negative effects of cytokines in the heart. Abstract of Paper Presented at the Endocrine Society's 83rd Annual Meeting, 2001.
22. Ikeda K, Tojo K, Tokudome G, Ohta M, Sugimoto K, Tamura T, Tajima N, Mochizuki S, Kawakami M, Hosoya T. Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. Mol Cell Bio Chem. 2003;252:25-32.
23. Watanabe F, Oki Y, Ozawa M, Masuzawa M, Iwabuchi M, Yoshimi T, Nishiguchi T, Iino K, Sasano H. Urocortin in human placenta and maternal plasma. Peptides. 1999;20:205-209.
24. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci. 2004;106:383-388.
25. Behan DP, De Souza EB, Lowry PJ, Potter E, Sawchenko P, Vale WW. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front Neuroendocrinol. 1995;16:362-382.
26. Seasholtz AF, Valverde RA, Denver RJ. Corticotropin-releasing hormone-binding protein: biochemistry and function from fishes to mammals. J Endocrinol. 2002;175:89-97.
27. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793-1800.
28. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J. 1995;16:741-751.
29. Cowie MR, Struthers AD, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. The Lancet. 1997;350:1349-1353.
30. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
31. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, Frampton CM, Richards AM. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab. 2004;89:1402-1409.
32. Hunt P, Richards A, Nicholls M, Yandle T, Doughty R, Espiner E. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP) : a new marker of cardiac impairment. Clin Endocrinol. 1997;47:287-296.
33. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993;76:832-838.
34. Yandle TG, Espiner EA, Nicholls MG, Duff H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab. 1986;63:72-79.
35. Prickett TCR, Yandle TG, Nicholls MG, Espiner EA, Richards AM. Identification of amino-terminal pro-c-type natriuretic peptide in human plasma. Biochem Biophys Res Commun. 2001;286:513-517.
36. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin (1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem. 1998;44:571-577.
37. Kitamura K, Tanaka T, Kato J, Eto T, Tanaka K. Regional distribution of immunoreactive endothelin in porcine tissue: Abundance in inner medulla of kidney. Biochem Biophys Res Commun. 1989;161:348-352.
38. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.